

Prosigna.

BREAST CANCER ASSAY

2nd generation test
that more comprehensively
informs treatment decisions.



CE-IVD MARKED
GUIDELINES
RECOMMENDED

**More Accurate
Prognostic
Score**

**Intrinsic
Subtype
Identified**

**Clinico-
pathological
Factors
Integrated**

Prosigna® more accurately identifies the low-risk group with better outcomes and the high-risk group with worse outcomes¹.

2nd GENERATION ASSAY (Prosigna®)

- 50 genes
- Gene expression + clinical features
- Local testing



27% of patients are **Low Risk** with 92.3% rate of DRFS*

38% of patients are **Int. Risk** with 79.6% rate of DRFS*

35% of patients are **High Risk** with 69.9% rate of DRFS*

- No recurrence
- Recurrence

10 YEARS PROGNOSIS

1st GENERATION ASSAY

- 21 genes
- Gene expression only
- Samples need to be sent to the US



50% of patients are **Low Risk** with 85.4% rate of DRFS*


31% of patients are **Int. Risk** with 79.8% rate of DRFS*

19% of patients are **High Risk** with 74.9% rate of DRFS*

- No recurrence
- Recurrence

5 YEARS PROGNOSIS

Clinically Validated Algorithm Generates a Prosigna® Score for Each Patient.




*DRFS: Distant Recurrence Free Survival. The probability of developing recurrence were obtained from a bespoke data analysis of the TransATAC study (Sestak I, Dowsett M, Cuzick J. NICE Request - TransATAC Data Analysis -2017. Illustration adapted from Harnan S, et al. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer Health Technol Assess. 2019 Jun;23(30):1-328.

How does the Prosigna® Assay work?

1

Extract RNA from FFPE* tumour sample



2

Test RNA using Prosigna® Assay on the nCounter Analysis System



3


Capture expression profile of patient's tumour



4

Patient Report

- Intrinsic Subtype identified
- Risk of Recurrence (ROR) within 10 years
- Risk of Recurrence (ROR) 5-10 years (late relapse)
- Clinicopathological factors like tumour size and nodal status incorporated in the score




*FFPE: Formalin Fixed Paraffin Embedded Tissue.

More **comprehensive information**
for better **treatment decisions.**

Prosigna[®]
BREAST CANCER ASSAY




Provides more accurate prognosis which is the **foundation of treatment recommendations**¹.



Prosigna[®] combines **tumour gene expression and clinico-pathological factors** in a single 10-year Risk of distant Recurrence (ROR) score^{2,3}.



The only breast cancer prognostic test identifying the **four PAM50 molecular subtypes**.



Easy access to local testing with **faster turnaround times**.

1. Sestak I, Buus R, Cuzick J, *et al*. JAMA Oncol. 2018; 4(4):545-553

2. Kos *et al*. Breast Cancer Res, 2014, 16:103

3. Alexandre *et al*. Cancer Manag Res, 2019; 11: 10353-10373